Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | Camzyos (mavacamten) - (SCOUT-HCM) | Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) | Phase 3 | Data Released | Oral | Cardiology |
| Bristol-Myers Squibb Company | BNT327-06 | First line NSCLC | Phase 2/3 | Enrollment Initiation | Intravenous | Oncology |
| Bristol-Myers Squibb Company | BMS-986504 (PRMT5 inhibitor) - (MountainTAP-30) | 1L Metastatic PDAC (with Homozygous MTAP deletion) | Phase 2/3 | Ongoing | oral | Oncology |
| Bristol-Myers Squibb Company | Iza-bren (izalontamab brengitecan, EGFR x HER3 ADC) - (IZABRIGHT-Breast01) | 1L Triple Negative Breast Cancer (TNBC) | Phase 2/3 | Ongoing | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Adagrasib (MRTX849) with pembrolizumab - (KRYSTAL-7) | Non-Small Cell Lung Cancer (NSCLC) | Phase 2/3 | Data Released | Oral and intravenous | Oncology |
| Bristol-Myers Squibb Company | Milvexian - (AXIOMATIC-TKR) | Venous thromboembolism (VTE) prevention post total knee replacement (TKR) surgery | Phase 2 | Data Released | Oral | Anticoagulant |
| Bristol-Myers Squibb Company | CELMoD (CC-99282) | Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) | Phase 2 | Ongoing | oral | Oncology |
| Bristol-Myers Squibb Company | BNT327-02 | 1-2L Metastatic Triple-negative breast cancer (TNBC) | Phase 2 | Data Released | Intravenous | Oncology |
